Carcinoma of the paranasal sinuses results of a prospective pilot study

Knegt, P.; Jong, Pieter C. De; Andel, J.G. van; Boer, Maarten F. de; Eykenboom, Wilhelmina; Schans, Enno Van Der

doi:10.1002/1097-0142(19850701)56:1<57::aid-cncr2820560110>3.0.co;2-#

Cited by 80 publications

(22 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 He also noticed that by this multimodality approach, mutilation was clearly reduced with 2-and 5-year survival rates of 76% and 65%, respectively. Squamous and undifferentiated histologic conditions displayed a 52% 5-year survival rate and adenocarcinomas a 100% 5-year survival rate.…”

Section: Discussionmentioning

confidence: 89%

Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne state university

LoRusso

Tapazoglou

Kish

et al. 1988

Cancer

View full text Add to dashboard Cite

The role of chemotherapy in the management of patients with cancer of the paranasal sinus has not been defined. An analysis of 24 evaluable patients treated with chemotherapy as part of their overall therapy was performed. There were 16 male patients and eight female patients. Sixteen patients were previously untreated and eight had recurrent disease after surgery and/or radiotherapy. Six of the previously untreated patients had metastatic disease on presentation (four central nervous system (CNS) and two lung), and four recurrent patients had CNS involvement. The majority of patients (78%) had squamous cell carcinoma. The chemotherapy regimens included cisplatin (CDDP), vincristine (VCR), and bleomycin (COB), 5-fluorouracil (5-FU) infusion and CDDP, or 5-FU/CDDP and methotrexate (MTX). All patients had computed tomography (CT) measurable disease. Previously untreated patients underwent surgery and/or radiotherapy postchemotherapy. The overall response rate to chemotherapy for previously untreated patients was 82% (complete response [CR] 44%, partial response [PR] 38%) and for recurrent patients 88% (CR 38%, PR 50%). Predominant toxicities were nausea, vomiting, myelosuppression, mucositis, and renal impairment. The median survival of the previously untreated patients, based on response to chemotherapy, was as follows: CR 21+ months (range, 10+ to 81 months), PR 13.5 months (range, 2 to 21 months), and no response (NR) 3 months (range, 1 to 7 months). The median survival of patients with recurrent disease was as follows: CR 16 months, PR 13.5 months, and NR 5 months. We conclude that patients with paranasal cancers are responsive to CDDP-containing combinations. The role of adjuvant chemotherapy in previously untreated, locally advanced patients needs to be demonstrated by future randomized trials.

show abstract

Section: Discussionmentioning

confidence: 89%

Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne state university

LoRusso

Tapazoglou

Kish

et al. 1988

Cancer

View full text Add to dashboard Cite

show abstract

“…This consists of surgical debulking followed by topical chemotherapy combined with frequent necrotomy. 12 In the period January 1976 through December 1988, these patients also received low-dose radiotherapy (ie, 2ϫ2 Gy preoperatively and 5ϫ2 Gy postoperatively). However, in consultation with our radiotherapy colleagues it was believed that this low-dose radiotherapy was insufficient to have any influence on the results.…”

Section: Methodsmentioning

confidence: 99%

Adenocarcinoma of the Ethmoidal Sinus Complex

Knegt¹,

Ah‐See²,

Velden³

et al. 2001

Arch Otolaryngol Head Neck Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…8,9,46,[197][198][199] Nevertheless, several reports related outcomes better than ours for patients with squamous cell carcinoma, 48,56,106,100,110,117,132,137,147,160,168,176 for patients with glandular carcinoma, 160,168,184 and for patients with adenocarcinoma. 136,146 The systematic review revealed a steady improvement in treatment results for patients with squamous cell carcinoma and glandular carcinoma (Fig. 6, top).…”

Section: Histologymentioning

confidence: 98%

“…154,184,185 The use of hyperfractionation 11,142 or neutron beam irradiation 142 does not seem to modify the cure rates drastically. Although the results of a few recent articles that included chemotherapy in the treatment protocol are encouraging, with 5-year survival rates Ͼ 50%, 34,40,136,137,173 it remains unclear whether the addition of chemotherapy to other aggressive treatment regimens provides a clear advantage in local control or survival.…”

Section: Treatment Modalitymentioning

confidence: 99%